People · Operator
Named in public records as an officer, director or promoter · active 2021–2022 · Pharma, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Neurexis Therapeutics, Inc. | — | Pharma | Pre-Seed | $500K | $16.1M | 2021 |
| Cellia Science, Inc. | — | Other | Pre-Seed | $250K | $2.1M | 2022 |
Michael Artinger at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Artinger on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Calvin Goforth | 1 | 25 |
| Calvin Goforth | 1 | 10 |
| Fenel Eloi | 1 | 3 |
| Kelly Mabry | 1 | 1 |
| Mark Wagstaff | 1 | 1 |
| Ulli Calvin Bayer | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.